August 2010 in “Oncology Times” This article discusses the approval and perceived potential of Provenge, a new prostate cancer vaccine, highlighting its capability to extend survival in certain patients while also noting ongoing debates about its cost and mechanisms; it reports no new clinical results.
2 citations
,
January 2006 in “Publicatio UEPG Ciencias Biologicas e da Saude” This review discusses the potential of dental stem cells from deciduous and permanent teeth for tissue regeneration and reports no new experimental results.
June 2011 in “Oncology times” This article covers discussions from the Society of Urologic Oncology Annual Meeting outlining that new therapies, such as Provenge, Prostvac, and denosumab, are making the treatment of advanced prostate cancer more complex but may offer extended survival benefits.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.